Totally agree. Scripts are going to rise, both for Amarin and generics. I don't care if generics take 50,000 scripts each week if Amarin eventually hits 200,000. Once the sales force can meet with doctors and doctors start pitching Vascepa to each other, prescriptions are going to see a nice rise.
Don't underestimate the protection Amarin receives by United Healthcare's decision not to cover generics at all. It's the biggest healthcare insurance company out there with 14 percent of the market, perhaps even a higher percentage of the population in areas like the Northeast where a lot of Vascepa prescriptions are written. And it's possible that other insurance companies might follow its decision regarding generics.
News 
Market Data 
Discover 
AI
